Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Autonomic Technologies Raises $38M For On-Demand Neurostim

This article was originally published in Start Up

Executive Summary

Paris-based Edmond de Rothschild Investment Partners was the major and lead financer of May's $38 million Series D round for Autonomic Technologies, which is developing the Pulsante microstimulator for on-demand treatment of cluster headache.

You may also be interested in...



Device/Diagnostics Quarterly Deal Statistics, Q2 2015

At $1.8 billion, Q2 device financing nearly doubled the Q1 total, mainly from an increase in IPOs and early VC rounds, and acquisitions were slightly higher at $4.7 billion. Diagnostics funding also increased to $784 million from Q1's $597 million, and Danaher's monster $13.8 billion buy of life sciences company Pall headlined the second quarter's $15.6 billion total in diagnostics M&A activity.

Novel Devices Penetrate Migraine Headache Market

Several new device-based therapies are emerging designed to fill the treatment gap for migraine suffers who do not respond to traditional migraine therapies. These novel treatments include a headband-like device designed to stimulate the trigeminal nerve and an image-guided intranasal interventional treatment.

QUOTED. 6 May 2020. Paul Diaz.

Myriad has sold several business units as it narrows its focus to oncology, women's health and mental health diagnostics. CEO Paul Diaz says the moves will allow the company to be a market leader.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT038039

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel